Welcome to our dedicated page for Painreform news (Ticker: PRFX), a resource for investors and traders seeking the latest updates and insights on Painreform stock.
PainReform Ltd. (Nasdaq: PRFX) generates news across two main areas: specialty pharmaceutical development for post-surgical pain and ophthalmology, and AI-driven solar and energy analytics through its DeepSolar platform. Company updates often highlight progress in extended-release drug-delivery technologies and in advanced digital tools for managing solar assets.
On the pharmaceutical side, news items cover developments in PRF-110, PainReform’s oil-based ropivacaine formulation for localized post-operative analgesia, and the OcuRing™-K program acquired through its majority investment in LayerBio. Releases describe preclinical and clinical milestones for OcuRing-K, including Phase I safety data in cataract surgery patients and R&D assessments showing that the sustained-release matrix can incorporate multiple drug entities such as corticosteroids and NSAIDs. These updates provide insight into how the company is pursuing dropless, sustained-release approaches to post-cataract pain and inflammation management.
In parallel, DeepSolar-related news focuses on AI-based solar analytics and energy optimization. Coverage includes the development of DeepSolar Predict, an AI forecasting module for photovoltaic systems advanced within the NVIDIA Connect program, the launch of Smart TDD for solar technical due diligence, and progress on an automated reporting engine that consolidates operational data into tailored performance reports. PainReform has also reported on pilot and commercial engagements for DeepSolar, such as a 92MW project with Econergy Renewable Energy.
Investors and observers can use this news feed to follow regulatory and clinical steps for PainReform’s pharmaceutical candidates, as well as product launches, technology collaborations, and commercial milestones in its DeepSolar business. Regular updates provide context on how the company advances its dual focus on non-opiate pain management and renewable-energy analytics.
PainReform Ltd. (Nasdaq: PRFX), a clinical-stage specialty pharmaceutical company, will have CEO Ilan Hadar present at the Sequire Investor Summit from April 24-26, 2023, in San Juan, Puerto Rico. Hadar's presentation is scheduled for April 26th at 1:30 PM ET. The summit will feature over 40 presentations from public companies, with opportunities for attendees to engage in one-on-one meetings and networking events. PainReform is focused on reformulating established therapeutics, with PRF-110 as its lead product targeting post-operative pain relief. This product is currently in Phase III clinical trials and utilizes a proprietary drug-delivery system designed for extended pain relief. For more information about the summit, visit puertorico.srax.com.
PainReform Ltd. (Nasdaq: PRFX) has completed the first part of its Phase 3 clinical trial for PRF-110, enrolling 15 patients undergoing unilateral bunionectomy. This trial aims to evaluate the analgesic efficacy and safety of PRF-110, which is applied directly into the surgical site for extended pain relief. The initial phase provided training for surgeons on optimal application methods, and results on pharmacokinetics will be available in May 2023. The second phase will involve approximately 400 patients across seven sites, comparing PRF-110 with ropivacaine and placebo.
PainReform Ltd. (Nasdaq: PRFX) provided a business update for 2022, marking significant advancements in the clinical development of PRF-110, its lead drug candidate targeting post-operative pain relief. The initiation of a Phase 3 clinical trial for bunionectomy has commenced, focusing on a safety pharmacokinetic study with 15 patients in Texas, with results expected in May 2023. Following this, a larger trial involving 400 patients will evaluate pain reduction over 72 hours. Financially, the company recorded a net loss of approximately $8.8 million and has approximately $10.2 million in cash as of December 31, 2022.
PainReform Ltd. (Nasdaq: PRFX) has initiated a Phase 3 clinical trial for its lead drug candidate, PRF-110, targeting post-operative pain relief following bunionectomy. The trial comprises two parts: an open-label safety study with 15 patients, followed by a double-blind study with around 400 patients across multiple sites. PRF-110 aims to provide localized, extended analgesia without the need for repeated dosing, addressing the opioid crisis. Initial pharmacokinetic data is expected in May 2023, with potential to capture a share in the $12 billion post-operative pain market if successful.
FAQ
What is the current stock price of Painreform (PRFX)?
What is the market cap of Painreform (PRFX)?
